Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies

NCT00984217 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00984217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00984217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Lead sponsor
University of Pittsburgh
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2011
Completion date
August 31, 2011
Enrollment
0 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

adenoma, pleomorphic, mixed salivary gland tumor, salivary gland tumor, mixed, syringoma, chondroid